A profile on the FoundationFocus CDxBRCA tests

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012 Sept;120(3):612–618.
   PubMed Web of Science ®Google Scholar
• Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006 Sep;108(3 Pt 1):521–528.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Monk BJ, Sood AK, et al. Latest research and clinical treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr;10(4):211–224.
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistance ovarian cancer. Drugs. 2011 Jul 30;71(11):1397–1412.
   PubMed Web of Science ®Google Scholar
• Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep. 2006 Nov;8(6):448–454.
   PubMedGoogle Scholar
• Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009 Sep;40(9):1213–1223.
   PubMed Web of Science ®Google Scholar
• Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991 Mar;9(3):389–393.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Randall LM, Pothuri B, Swisher EM, et al. Multi-disciplinary summit on genetics services for women with gynecologic cancers: a society of gynecologic oncology white paper. Gynecol Oncol. 2017 Aug;146(2):217–224.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004 Apr 1;10(7):2473–2481.
   PubMed Web of Science ®Google Scholar
• Goodheart MJ, Rose SL, Hattermann-Zogg M, et al. BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet. 2009 Aug;76(2):161–167.
   PubMed Web of Science ®Google Scholar
• Staples J, Goodman A. Chapter 14: PARP inhibitors in ovarian cancer. In: Diaz-Padilla I, editor. Ovarian cancer a clinical and translational update. InTech; 2013. [Accessed 1.26.2020]. Available from: http://www.intechopen.com/books/ovarian-cancer-a-clinical-and-translational-update/parp-inhibitors-in-ovarian-cancer
   Google Scholar
• Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005 Dec 15;104(12):2807–2816.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye SB. New Strategies in the treatment of ovarian cancer: current clinical perspectives, and future potential. Clin Cancer Res. 2013 Mar 1;19(5):961–968.
   PubMed Web of Science ®Google Scholar
• FoundationFocus Technical information. [cited 2018 Jun 1]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160018c.pdf
   Google Scholar
• FoundationFocus Technical information. [cited 2018 Jun 1]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160018S001c.pdf.
   Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defects in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr 14;434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005 Apr 14;434(7035):913–917.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017 Mar 17;355(633):1152–1158.
   PubMedGoogle Scholar
• Hopkins TA, Shi Y, Rodriguez LE, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res. 2015 Nov;13(11):1465–1477.
   PubMed Web of Science ®Google Scholar
• Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010;70:5389–5398.
   PubMed Web of Science ®Google Scholar
• Patel A, Sarkaria J, Kaufmann SH. Nonhomologous end-joining drives PARP inhibitor synthetic lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108:3406–3411.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123–134.
   PubMed Web of Science ®Google Scholar
• Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly(ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010 Aug 1;29(22):3570–3576.
   Google Scholar
• Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014 Feb 1;20(3):764–775.
   PubMed Web of Science ®Google Scholar
• Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predicts homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012 Nov 6;107(10):1776–1782.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555–3561. [Erratum, J Clin Oncol 2010;28:4868.].
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tishchkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or undifferentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicenter, open-label, non-randomised study. Lancet Oncol. 2011 Sep;12(9):852–861.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382–1392.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852–861.
   PubMed Web of Science ®Google Scholar
• Gunderson CC, Moore KN. BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Expert Rev Mol Diagn. 2015 15;9:1111–1116.
   Google Scholar
• Kaufman B, Shapira-Frommer R, Schutzler RK, et al.  Olarparib monotherapy in patients with advanced cancer and germline BRCA 1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50.
   Google Scholar
• Kristeleit R, Shapiro GI, Burris HA, et al. A phase I-II study of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017 Aug 1;23(15):4095–4106.
   PubMed Web of Science ®Google Scholar
• Swisher EM, McNeish IA, Coleman RL, et al. ARIEL 2/3: an integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. J Clin Oncol. 2014;32(15_suppl):TPS5619–TPS5619.
   Web of Science ®Google Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016 Aug 1;22(15):3764–3773.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicenter, open-label, phase 2 trial. Lancet Oncol. 2017 Jan;18(1):75–87.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949–1961.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Harrell MI, Lin K, et al. BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1. Gynecol Oncol. 2017;145(S1):5.
   Google Scholar
• Roscoe DM, Hu Y-F, Philip R. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Rev Mol Diagn. 2015;15(7):869–880.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam S, Beaver JA, Horton S, et al. FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res. 2017 Dec 1;23(23):7165–7170.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Brusco L, Daniels M, et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. 2016 May;27(5):795–800.
   PubMed Web of Science ®Google Scholar
• Winter C, Nilsson MP, Olsson E, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016 Aug;27(8):1532–1538.
   PubMed Web of Science ®Google Scholar
• Schrader KA, Cheng DT, Joseph V, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016 Jan;2(1):104–111.
   PubMed Web of Science ®Google Scholar
• Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825–835.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Ovarian cancer (Version 2.2018). [cited Jul]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
   Google Scholar
• Banda K, Swisher EM, Wu D, et al. Somatic reversion of germline BRCA2 mutation confers resistance to poly(ADP-ribose) polymerase inhibitor therapy. JCO Precis Oncol. 2018;2:1–6.
   PubMed Web of Science ®Google Scholar
• Callihan P, Ghazalpour A, Edenfield J A revertant of the pathogenic germline mutation in BRCA1 as a possible cause of breast cancer chemoresistance.
   Google Scholar
• Carneiro BA, Collier KA, Nagy RJ, et al. Acquired resistance to poly(ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restore both germline and somatic loss-of-function mutations. JCO Precis Oncol. 2018;2:1–8.
   PubMed Web of Science ®Google Scholar
• Goodall J, Mateo J, Yuan W, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017 Sep;7(9):1006–1017.
   PubMed Web of Science ®Google Scholar
• Sun JX, He Y, Sanford E, et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018 Feb 7;14(2):e1005965.
   PubMed Web of Science ®Google Scholar
• Berchuck A, Secord AA, Moss HA, et al. Maintenance poly (ADP-ribose) polymerase inhibitor therapy for ovarian cancer: precision oncology or one size fits all? J Clin Oncol. 2017 Dec 20;35(36):3999–4002.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JASelle F, et al. SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274–1284
   Google Scholar
• Mirza MR, Monk BJHerrstedt AM, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018 Dec 27;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar